Cargando…

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis

Detalles Bibliográficos
Autores principales:	Loscocco, Giuseppe G., Santi, Raffaella, Carrai, Valentina, Coltro, Giacomo, Mannelli, Francesco, Guglielmelli, Paola, Vannucchi, Alessandro M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Images
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796949/ https://www.ncbi.nlm.nih.gov/pubmed/35622069 http://dx.doi.org/10.1111/ijlh.13902

Ejemplares similares

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
por: Loscocco, Giuseppe G, et al.
Publicado: (2020)

Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms
por: Guglielmelli, Paola, et al.
Publicado: (2010)

Chronic Myeloproliferative Neoplasms: a Collaborative Approach
por: Pieri, Lisa, et al.
Publicado: (2010)

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
por: Bogani, Costanza, et al.
Publicado: (2013)

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
por: Vannucchi, Alessandro M, et al.
Publicado: (2009)

Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms: Friend and Enemy, Depending on Circumstances
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2023)

Hereditary hemochromatosis
por: Geller, Stephen A., et al.
Publicado: (2015)

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
por: Coltro, Giacomo, et al.
Publicado: (2022)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

Hereditary hemochromatosis and JAK2‐positive polycythemia vera
por: Radwan, Ahmed, et al.
Publicado: (2021)

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
por: Vannucchi, A M, et al.
Publicado: (2014)

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
por: Guglielmelli, Paola, et al.
Publicado: (2021)

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
por: Barbui, Tiziano, et al.
Publicado: (2018)

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Case Report: Concomitant Diagnosis of Plasma Cell Leukemia in Patient With JAK2 Positive Myeloproliferative Neoplasm
por: Kurian, Christine J., et al.
Publicado: (2020)

Mouse models of myeloproliferative neoplasms: JAK of all grades
por: Li, Juan, et al.
Publicado: (2011)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
por: Bader, Michael Stephan, et al.
Publicado: (2022)

P985: THE ALLELIC RATIO OF DRIVER AND ASXL1 MUTATIONS IS PROGNOSTICALLY RELEVANT IN PMF
por: Coltro, G., et al.
Publicado: (2022)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms
por: Tapper, William, et al.
Publicado: (2015)

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
por: Tefferi, Ayalew, et al.
Publicado: (2018)

The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
por: de Freitas, Renata Mendes, et al.
Publicado: (2013)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
por: Bartalucci, Niccolò, et al.
Publicado: (2013)

Myelodysplastic syndrome/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
por: Tasleem, Azka, et al.
Publicado: (2021)

PB2251: TWO POLYCYTHEMIA VERA PATIENTS WITH A DIAGNOSIS OF CONCOMITANT HEREDITARY HEMOCHROMATOSIS
por: Kiper Unal, H. D., et al.
Publicado: (2022)

Hereditary Hemochromatosis and Iron Metabolism
por: Carlson, Joyce, et al.
Publicado: (2001)

Polycythemia and Anemia in Hereditary Hemochromatosis
por: Khan, Adnan Aman, et al.
Publicado: (2020)

Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis
por: Mannelli, Francesco, et al.
Publicado: (2022)

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
por: Romagnoli, Simone, et al.
Publicado: (2021)

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms
por: Goldin, Lynn R, et al.
Publicado: (2009)

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
por: Ma, Wanlong, et al.
Publicado: (2010)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bmheo7qakud68qn0qvm55940fb